The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN)

Cardiometabolic Syndrome Clinical Trial

— PICMAN  

Official title:

The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN) Across National University Health System (NUHS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06062836
• Other study ID #: PICMAN
• Status: Recruiting
• Start date: April 1, 2022
• Est. completion date: April 2024

Study information

• Verified date: April 2023
• Source: National University Hospital, Singapore
• Contact: Mayank Dalakoti
• Phone: +6566011036
• Email: mayank_dalakoti[@]nuhs.edu.sg
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Background Changes in metabolism and mitochondrial function appear to precede cardiac dysfunction, with much evidence supporting metabolic dysregulation as one of the earliest precursors of cardiovascular disease. We hypothesise that quantifiable metabolic inflexibility may be representative of an individual in his/her silent, but high-risk progression towards insulin resistance, diabetes and cardiovascular disease. The platform for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) across National University Health System (NUHS) is a pilot, prospective, multi-ethnic cohort study in Singapore.

Through extensive phenotyping in a preventive cardiology cohort, the central aim is to define the metabolic flexibility range in a cohort of individuals at elevated risk of atherosclerotic cardiovascular disease, to correlate metabolic flexibility to measures of cardiometabolic health, including diastolic dysfunction, coronary and cerebral atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease.

Description:

Aims

1. Define norms for metabolic flexibility in a multi-ethnic Southeast Asian cohort of individuals without manifest ASCVD

2. Understand the association of metabolic inflexibility with cardiovascular measures of diastolic dysfunction and coronary and cerebral atherosclerosis

3. Understand the association of metabolic inflexibility with measures of body fat distribution

4. Understand the correlation between metabolic flexibility and insulin sensitivity along the spectrum of subclinical cardiovascular disease and severity of non-alcoholic fatty liver disease

5. Associations of the gut microbiome as well as metabolomic and molecular markers with cardio-cerebrovascular measures, metabolic flexibility and liver fibrosis

The PICMAN study seeks to lay the foundations for further future larger scale and more experimentally ambitious studies based on the overarching hypothesis that metabolic flexibility is an early marker in subclinical cardiovascular disease, indicating a point of timely intervention where the disease process is still reversible. The importance of a deeply-phenotyped local cohort will allow us to study the progression of CVD in seemingly well adults, converging imaging, biochemical, metabolic markers, and 'omics analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: April 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients aged 21-70 at screening

• 10-year ASCVD risk > 5% measured by QRISK 3 calculator

Exclusion Criteria:

• Established DM (Prior diagnosis, long term medications or HbA1c >=6.5)

• Established CVD, such as ischemic heart disease, cerebrovascular accident, heart failure, atrial fibrillation

• Pregnancy

• Known contraindications to CT scan, such as allergy to contrast

Related Conditions & MeSH terms

• Cardiometabolic Syndrome
• Metabolic Syndrome

Locations

Country	Name	City	State
Singapore	National University Health System	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Metabolic flexibility	Metabolic flexibility will be calculated (deltaRQ)	Up to 5 years